Abstract
Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and / or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligandreceptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.
Keywords: Diphtheria Fusion Protein Therapy, Chemoresistant Malignancies, Pseudomonas exotoxin, saporin, gelonin, diphtheria toxin, genetically engineered diphtheria toxin, cancer therapy, corynebacterium diphtheriae, iymphocytic leukemia cll
Current Cancer Drug Targets
Title: Diphtheria Fusion Protein Therapy of Chemoresistant Malignancies
Volume: 2 Issue: 1
Author(s): Arthur E. Frankel, Patrick Rossi, Timothy M. Kuzel and Francine Foss
Affiliation:
Keywords: Diphtheria Fusion Protein Therapy, Chemoresistant Malignancies, Pseudomonas exotoxin, saporin, gelonin, diphtheria toxin, genetically engineered diphtheria toxin, cancer therapy, corynebacterium diphtheriae, iymphocytic leukemia cll
Abstract: Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and / or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligandreceptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.
Export Options
About this article
Cite this article as:
Frankel E. Arthur, Rossi Patrick, Kuzel M. Timothy and Foss Francine, Diphtheria Fusion Protein Therapy of Chemoresistant Malignancies, Current Cancer Drug Targets 2002; 2 (1) . https://dx.doi.org/10.2174/1568009023333944
DOI https://dx.doi.org/10.2174/1568009023333944 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tc-99m Radiolabeled Alendronate Sodium Microemulsion: Characterization and Permeability Studies Across Caco-2 Cells
Current Drug Delivery Mechanistic Studies of Inactivation of Glutathione S-transferase Pi Isozyme by a Haloenol Lactone Derivative
Medicinal Chemistry Use of Corticosteroids in Critically Ill Septic Patients: A Review of Mechanisms of Adrenal Insufficiency in Sepsis and Treatment
Current Drug Targets Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Studies on the pIC50 of 4,5-Diarylisoxazole as HSP90 Inhibitors
Letters in Drug Design & Discovery Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Toxic Metals in Herbal Medicines. A Review
Current Bioactive Compounds Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Cytokine Targeting in Osteoarthritis
Current Drug Targets Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Editorial [Hot Topic: Tumor Immunology (Guest Editors: Bharat H. Joshi and Raj K. Puri)]
Current Molecular Medicine Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry Analysis of the Relative Movements Between EGFR and Drug Inhibitors Based on Molecular Dynamics Simulation
Current Bioinformatics Hypoxia Inducible Factor 1 as a Therapeutic Target in Ischemic Stroke
Current Medicinal Chemistry Applications of Natural Polymeric Materials in Solid Oral Modified-Release Dosage Forms
Current Pharmaceutical Design Point-of-Care Genetic Tests for Infectious Disease: Legal Considerations
Current Pharmacogenomics and Personalized Medicine Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Rapid Biosynthesis of Gold Nanoparticles Using Aqueous-ethanoic Leaf Extract of Heartleaf Moonseed: Characterization and Effect of pH on its Synthesis
Current Nanomaterials